LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of Phase I is to establish the maximum tolerated dose (MTD) of
ruxolitinib in combination with carfilzomib and dexamethasone. The primary objective of phase
II is to evaluate progression-free survival (PFS) at 4 months in multiple myeloma subjects
who receive the combination treatment carfilzomib, dexamethasone, and ruxolitinib.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Saad Z. Usmani, MD Shebli Atrash
Collaborators:
Amgen Incyte Corporation Multiple Myeloma Research Consortium